Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

NCT07193160 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)

Interventions

DRUG: Sacituzumab Tirumotecan
DRUG: Furmonertinib

Sponsor

Fudan University